Literature DB >> 11146232

Intratumour heterogeneity in microvessel oxyhaemoglobin saturations.

K Måseide1, E K Rofstad.   

Abstract

The aim of the present study was to examine intratumour heterogeneity in microvessel oxyhaemoglobin (HbO2) saturations in human melanoma xenografts. The HbO2 saturations, measured with a cryospectrophotometric micromethod, were found to vary substantially within single tumours. All tumours showed a decrease in overall HbO2 saturation from the periphery towards the centre, although the profiles could vary substantially between individual tumours. Local differences could be large, and many tumours had HbO2 saturations spanning from 0 to 100% in peripheral regions. In central tumour regions, low saturations were prevailing although subregions of intermediate and high saturations could also be found.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11146232     DOI: 10.1016/s0304-3835(00)00670-4

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  3 in total

1.  High resolution ultra high field magnetic resonance imaging of glioma microvascularity and hypoxia using ultra-small particles of iron oxide.

Authors:  Gregory A Christoforidis; Ming Yang; Marinos S Kontzialis; Douglas G Larson; Amir Abduljalil; Michelle Basso; Weilian Yang; Abhik Ray-Chaudhury; Johannes Heverhagen; Michael V Knopp; Rolf F Barth
Journal:  Invest Radiol       Date:  2009-07       Impact factor: 6.016

2.  Temporal heterogeneity in blood supply in human tumor xenografts.

Authors:  Kjetil G Brurberg; Jon-Vidar Gaustad; Camilla S Mollatt; Einar K Rofstad
Journal:  Neoplasia       Date:  2008-07       Impact factor: 5.715

3.  Targeting the tumour vasculature: exploitation of low oxygenation and sensitivity to NOS inhibition by treatment with a hypoxic cytotoxin.

Authors:  Jennifer H E Baker; Alastair H Kyle; Kirsten L Bartels; Stephen P Methot; Erin J Flanagan; Andrew Balbirnie; Jordan D Cran; Andrew I Minchinton
Journal:  PLoS One       Date:  2013-10-28       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.